Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SLC27A1 | Q6PCB7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2541760 | 0.92 | ACHE (0.42) | SMN1; SMN2USP2LMNATSHRPIK3CA | |
| SCHEMBL2543867 | 0.90 | CLK1 (0.58) | CLK1SMN1; SMN2USP2LMNATSHR | |
| SCHEMBL1836576 | 0.90 | ALDH1A1 (0.55) | CLK1SMN1; SMN2USP2LMNATSHR | |
| SCHEMBL2541325 | 0.89 | CLK1 (0.47) | CLK1SMN1; SMN2USP2LMNATSHR | |
| SCHEMBL2544871 | 0.89 | CLK1 (0.47) | CLK1SMN1; SMN2USP2LMNATSHR | |
| SCHEMBL2543183 | 0.88 | CLK1 (0.48) | CLK1SMN1; SMN2USP2LMNATSHR | |
| SCHEMBL2542595 | 0.88 | ALDH1A1 (0.57) | CLK1SMN1; SMN2USP2LMNATSHR | |
| SCHEMBL2543731 | 0.88 | USP2 (0.39) | CLK1SMN1; SMN2USP2LMNATSHR | |
| SCHEMBL2543728 | 0.88 | CLK1 (0.47) | CLK1SMN1; SMN2USP2LMNATSHR | |
| SCHEMBL2547147 | 0.88 | CLK1 (0.56) | CLK1SMN1; SMN2USP2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263593-A1 | NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263593-A1 | NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS | TPMT, MET, PAICS | CLK1 1235/4885SMN1; SMN2 2888/4885USP2 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.